Finanz und Wirtschaft is reporting about RocketVax’s development of an effective and safe vaccine against SARS-CoV-2

A number of leading SARS-CoV-2 vaccine candidates use other viruses, such as adenoviruses tagged with just one coronavirus protein, particularly the spike protein which is required for the virus to enter cells.

However, it is unlikely that these vaccines will induce strong and lasting protection against SARS-CoV-2. We believe that it is important to develop vaccines that cover as many SARS-CoV-2 proteins as possible but without any pathogenic potential.

FOLLOW THIS LINK TO READ FULL ARTICLE ↗

Finanz und Wirtschaft is reporting about RocketVax’s development of an effective and safe vaccine against SARS-CoV-2

The development of a SARS-CoV-2 vaccine might be more complex than anticipated, and the first generation of vaccines may not provide the long-lasting, high-level protection that will be needed to end the many negative consequences of the global SARS-CoV-2 pandemic.